组蛋白甲基化酶SMYD3在前列腺癌组织的表达及对mTOR通路的影响

doi:10.6040/j.issn.1671-7554.0.2015.1257

摘要/Abstract

摘要： 目的探讨组蛋白甲基化酶SMYD3在前列腺癌组织的表达水平及其对前列腺癌细胞生长的影响。方法免疫组化染色检测33例前列腺癌及癌旁组织的SMYD3表达水平; siRNA及SMYD3过表达质粒分别转染前列腺癌LNCaP和PC3细胞,检测其对前列腺癌细胞系生长的影响;Western blotting检测前列腺癌细胞中mTOR通路相关蛋白表达水平。结果 SMYD3在前列腺癌组织的表达水平明显高于癌旁组织,且SMYD3在胞核胞浆中均可检测到;转染SMYD3 siRNA后处理组LNCaP细胞在不同生长时期均少于对照组;而PC3细胞在转染SMYD3过表达质粒后细胞数则多于对照组。处理后,LNCaP细胞p-mTOR、p-p70S6K基因表达降低(P<0.05),而p-4EBP-1蛋白表达上升(P<0.05);PC3细胞呈现一致趋势。结论前列腺癌组织中SMYD3表达水平高于癌旁组织,且在胞核胞浆中均有表达;SMYD3表达可以促进前列腺癌细胞的生长;且可通过激活mTOR基因,参与mTOR通路的调节,影响前列腺癌细胞系的生长。

关键词: mTOR通路, siRNA, 前列腺肿瘤, SMYD3

Abstract: Objective To determine the expression of histone methyltransferase SMYD3 in prostate cancer tissues and to explore its role and mechanism in prostate cancer progression. Methods The expression of SMYD3 in 33 pairs of prostate cancer tissues and matched non-tumor tissues were detected with immunohistochemical staining. Prostate cancer cell line LNCaP and PC3 were transfected with siRNA and SMYD3 over-expressing vectors, respectively, to evaluate their growth. The expressions of proteins involved in mTOR pathway were evaluated with Western blotting. Results Prostate cancer had over-expressed SMYD3 compared with non-tumor normal tissues. The SMYD3 expression could be found in both nucleus and cytoplasm. SMYD3 abundance had a positive correlation with cell proliferation. The number of LNCaP cells was lower in SMYD3 siRNA group compared with the control group, and the number of PC3 cells was higher in SMYD3-PC vector group than in the control group. The depletion of the enzyme could down-regulate the expression of p-mTOR(P<0.05)and p-p70S6K(P<0.05), while the expression of p-4EBP-1(P<0.05)could be up-regulated; the trend of protein expression in mTOR pathway in PC3 was similar to that in LNCaP. Conclusion SMYD3 is over-expressed in prostate cancer tissues compared with non-tumor tissues, and SMYD3 can be expressed both in nucleus and cytoplasm. The expression of SMYD3 can activate the growth of prostate cancer cells by activating mTOR pathway.

Key words: Prostate neoplasms, MTOR pathway, SiRNA, SMYD3

中图分类号:

R737.25

夏传友,李路超,李孝峰,颜克强, 张念昭,范医东,刘承. 组蛋白甲基化酶SMYD3在前列腺癌组织的表达及对mTOR通路的影响[J]. 山东大学学报（医学版）, 2016, 54(5): 12-16.

XIA Chuanyou, LI Luchao, LI Xiaofeng, YAN Keqiang, ZHANG Nianzhao, FAN Yidong, LIU Cheng. Expression of histone methyltransferase SMYD3 in prostate cancer tissues and its role in mTOR pathway[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(5): 12-16.

参考文献

[1] Hamamoto R, Furukawa Y, Morita M, et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells[J]. Nat Cell Biol, 2004, 6(8): 731-740.
[2] Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression[J]. J Carcinog, 2011, 23. doi:10.4103/1477-3163.83937.
[3] Liu C, Wang C, Wang K, et al. SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription[J]. J Natl Cancer Inst, 2013, 105(22): 1719-1728.
[4] Nishio K, Sakai K, Togashi Y. PI3K and mTOR pathway and molecular targeted agents[J]. Nihon Rinsho, 2015, 73(8): 1315-1322.
[5] Liu Y, Bi T, Dai W, et al. Lupeol induces apoptosis and cell cycle arrest of human osteosarcoma cells through PI3K/AKT/mTOR Pathway[J]. Technol Cancer Res Treat, 2015. pii: 1533034615609014.[Epub ahead of print]
[6] Follo MY, Manzoli L, Poli A, et al. PLC and PI3K/Akt/mTOR signalling in disease and cancer[J]. Adv Biol Regul, 2015, 57: 10-16. doi: 10.1016/j.jbior.2014.10.004. Epub 2014 Nov 26.
[7] Guo Z, Hu X, Xing Z, et al. Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway[J]. Mol Cell Biochem, 2015, 406(1-2): 111-119.
[8] Vieira FQ, Costa-Pinheiro P, Almeida-Rios D, et al. SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3[J]. Oncotarget, 2015, 6(15): 13644-13657.
[9] Bitting RL, Armstrong AJ. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer[J]. Endocr Relat Cancer, 2013, 20(3): R83-R99.
[10] Jiang SJ, Wang S. Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo[J]. Tumour Biol, 2015, 36(10): 8177-8184.
[11] 李刚, 闫若东, 穆中一, 等. mTOR对非激素依赖性前列腺癌的作用研究[J]. 肿瘤学杂志, 2013, 19(12): 947-953. LI Gang, YAN Ruodong, MU Zhongyi, et al. Study on the effect of mTOR on androgen-independent prostate cancer[J]. Journal of Chinese Oncology, 2013, 19(12): 947-953.
[12] Edlind MP, Hsieh AC. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance[J]. Asian J Androl, 2014, 16(3): 378-386.
[13] Park H, Kim Y, Sul JW, et al. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer[J]. Prostate, 2015, 75(15): 1747-1759.
[14] Ali AK, Nandagopal N, Lee SH. IL-15-PI3K-AKT-mTOR: a critical pathway in the life journey of natural killer cells[J]. Front Immunol, 2015, 6: 355. doi: 10.3389/fimmu.2015.00355. eCollection 2015.
[15] Guertin DA, Sabatini DM. Defining the role of mTOR in cancer[J]. Cancer Cell, 2007, 12(1):9-22.
[16] Yamamoto K, Ishida T, Nakano K, et al. SMYD3 interacts with HTLV-1 Tax and regulates subcellular localization of Tax[J]. Cancer Sci, 2011, 102(1): 260-266.
[17] Hayashi M, Deng L, Chen M, et al. Interaction of the hepatitis B virus X protein with the lysine methyltransferase SET and MYND domain-containing 3 induces activator protein 1 activation[J]. Microbiol Immunol, 2016, 60(1): 17-25.

相关文章 15

[1]	张士宝刘庆勇阮喜云陈杰张建军李宗武杨广笑王全颖. NT₄-SAC-HA₂-TAT融合基因表达载体的构建及鉴定[J]. 山东大学学报(医学版), 2209, 47(6): 15-19.
[2]	董伟,邢乃栋,吕家驹,刘帅,孙亮,曹庆伟,董宇昊,刘钊,丁森泰. 靶向抑制有丝分裂驱动蛋白治疗多西紫杉醇耐药前列腺癌的体外疗效[J]. 山东大学学报（医学版）, 2017, 55(9): 23-30.
[3]	韩博, 戚美, 谭薇薇, 杨木易. 去势抵抗性前列腺癌的发生发展机制及药物治疗新进展[J]. 山东大学学报（医学版）, 2015, 53(9): 1-7.
[4]	程翔宇, 邢锐, 邢召全, 郭兆新, 郭晓宇, 苏静, 孟力维, 刘照旭. 氯化两面针碱对前列腺癌细胞PC-3增殖与凋亡的影响[J]. 山东大学学报（医学版）, 2015, 53(9): 13-18.
[5]	姜慧钰, 王林, 潘继红. siRNA沉默PCSK6基因对胶原诱导性关节炎的影响[J]. 山东大学学报（医学版）, 2015, 53(12): 20-26.
[6]	王琛, 唐悦清, 闫磊, 焦伟, 周尊林, 徐忠华. 胰岛素对前列腺癌LNCaP细胞的抑制作用[J]. 山东大学学报（医学版）, 2014, 52(7): 22-27.
[7]	丁玲1,2，巩会平1，杜贻萌1，王欣1，张岩3，王旭平2，鹿庆华1. SIRT3 siRNA对ox-LDL刺激的人主动脉内皮细胞ICAM-1、E-selectin表达的影响[J]. 山东大学学报（医学版）, 2014, 52(4): 43-48.
[8]	王介忠1，韩波1，高聆2，杨文巍1，刘奉琴1，吕建利1，赵立健1 . CD40siRNA对EAM大鼠的作用及其对CD4+CD25+Treg的影响[J]. 山东大学学报（医学版）, 2014, 52(1): 1-4.
[9]	张晶1，王林2，3，夏平钿3，秦晓敏4，韩博3，4，郭秀丽1. 二甲双胍抑制人前列腺癌细胞上皮间质转化及其作用机制[J]. 山东大学学报(医学版), 2013, 51(9): 35-39.
[10]	郑懿，蒋伟，金讯波，王慕文，张沂南，夏庆华. 丙戊酸诱导前列腺癌自噬并促进SPARCL1蛋白的表达[J]. 山东大学学报(医学版), 2013, 51(7): 32-35.
[11]	刘洪丽，张友忠，吕昌帅，丁佰娟，王颉. 核仁素表达下调对宫颈癌细胞Hela生物学行为的影响[J]. 山东大学学报(医学版), 2013, 51(11): 46-50.
[12]	梁婷婷，张萍，马德美，朱琳. 靶向HPV16-E5的siRNA对TRAIL诱导宫颈癌Caski细胞凋亡的影响[J]. 山东大学学报(医学版), 2013, 51(10): 24-28.
[13]	李先哲1，司曼飞1,2，郭艳霞1，苑辉卿1. 抑癌基因PDLIM4在前列腺癌细胞中的差异表达[J]. 山东大学学报(医学版), 2013, 51(06): 34-39.
[14]	戚美1，杨晓庆1，王林1,2，张娟3，王妍3，韩博1,3. ETS基因重排在前列腺癌中的特征分析[J]. 山东大学学报(医学版), 2013, 51(06): 94-99.
[15]	韩博1,3,杨晓庆1,张晶2,刘文君3,刘龙3. SPINK1在前列腺癌中的基础及临床转化研究进展[J]. 山东大学学报(医学版), 2012, 50(8): 40-.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed